This TCM and Cancer Research Collection aimed to deliver high-level research of traditional Chinese medicine (TCM) in cancer characterized by scientific rigor and the potential to advance the field. The health burden of cancer is increasing globally. Recent decades have witnessed substantial improvements in cancer management, including theoretical research and clinical practice. TCM has shown promising therapeutic effects for cancer patients as an adjunctive treatment following surgery, chemotherapy, or radiotherapy. Researchers are actively investigating the molecular and cellular mechanisms underlying the therapeutic effects of TCM in cancer therapy. To apply the full potential of TCM in cancer treatment and broaden its application, the underlying mechanisms of TCM‐derived compounds and their clinical benefits in cancer must be further exploited.
We welcome submissions from the following research areas.
- Fundamental Research
- Discovery of new antitumor active substances in traditional Chinese medicine
- Structure-activity relationship and structural modification of antitumor monomer compositions in traditional Chinese medicine
- Antitumor Pharmacology, Toxicology, and Pharmacokinetics of Traditional Chinese Medicine
- Research and development of new formulations of traditional Chinese medicine to prevent and treat tumours
- Clinical Studies
- Clinical observation on antitumor effects of traditional Chinese medicine
- Study on the prevention and treatment of traditional Chinese medicine in the period of tumour recovery
- The intervention of traditional Chinese medicine on adverse events of tumour radiotherapy and chemotherapy
Studies on complex herbal extracts must characterize their chemical composition (e.g., HPLC fingerprinting analysis or quantization of major compounds). We welcome the following types of articles: original papers, reviews, and short communications.
Dr. Shusen Sun was a research scientist at Pfizer before his pharmacy career. He is an Associate Editor for Pharmaceutical Biology. His current research focuses on the effectiveness and safe use of medicines, pharmacovigilance, pharmacoepidemiology, and pharmacoeconomics.
Dr. Haibin Dai is a Professor and Chief Pharmacist in the Pharmacy Department of the Second Affiliated Hospital of the Zhejiang University School of Medicine. His research focuses on understanding the roles of Annexin A2 in ischemic brain damage, understanding the molecular mechanisms of glycation in diabetes that enhance ischemic stroke injury, and developing anti-AGE agents to treat stroke accompanied by diabetes.
Disclosure statement: Dr. Shusen Sun and Dr. Haibin Dai have no conflicts of interest to disclose regarding this work.
